Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?
Goutham Hassan Venkatesh, Raefa Abou Khouzam, Walid El‐Sayed, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

NK cells and solid tumors: therapeutic potential and persisting obstacles
Le Tong, Carlos Jiménez‐Cortegana, Apple H.M. Tay, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 98
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 93
The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Raefa Abou Khouzam, Rania F. Zaarour, Klaudia Brodaczewska, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Surface Functionalization of Gold Nanoparticles for Targeting the Tumor Microenvironment to Improve Antitumor Efficiency
K. Tan, Lionel Lian Aun In, Palanirajan Vijayaraj Kumar
ACS Applied Bio Materials (2023) Vol. 6, Iss. 8, pp. 2944-2981
Closed Access | Times Cited: 26
Proline metabolism shapes the tumor microenvironment: from collagen deposition to immune evasion
Emily Kay, Sara Zanivan, Alessandro Rufini
Current Opinion in Biotechnology (2023) Vol. 84, pp. 103011-103011
Open Access | Times Cited: 21
Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy
Raefa Abou Khouzam, Bassam Janji, Jérôme Thiery, et al.
Seminars in Cancer Biology (2023) Vol. 97, pp. 104-123
Closed Access | Times Cited: 18
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Adriana Petrazzuolo, Maria Chiara Maiuri, Laurence Zitvogel, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
Giimel Ajnai, Chun‐Chia Cheng, Tzu-Chun Kan, et al.
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 847-847
Open Access | Times Cited: 20
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Raefa Abou Khouzam, Jean‐Maríe Lehn, Hemma Mayr, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1235-1235
Open Access | Times Cited: 11
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Gwenyth J. Joseph, Douglas B. Johnson, Rachelle W. Johnson
Journal of bone oncology (2023) Vol. 43, pp. 100505-100505
Open Access | Times Cited: 11
Construction of a Multifunctional Nanodrug Delivery System Based on Tirapazamine and Glucose Oxidase: Its Antitumor Activity
X. Shi, Li Xu, Baoqing Liu, et al.
ChemistrySelect (2025) Vol. 10, Iss. 6
Closed Access
Fufang-Biejia-Ruangan Tablet targeting both cancer-associated fibroblasts and tumor cells by HIPPO-PI3K/AKT cascades in intrahepatic cholangiocarcinoma treatment
Yanyu Xu, Xiang Li, Miao Cui, et al.
Phytomedicine (2025), pp. 156690-156690
Closed Access
Exploring the potential of CAR-NK cell therapy in the management of head and neck cancer (HNC): a narrative review
Erfan Zare, S Mostafavi, Naeim Norouzi, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 4, pp. 2026-2034
Open Access
Immunocytes in the tumor microenvironment: recent updates and interconnections
Jiyao Yu, Li Fu, Rui Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Hypoxia and programmed cell death-ligand 1 expression in the tumor microenvironment: a review of the effects of hypoxia-induced factor-1 on immunotherapy
Fateme Khani Chamani, Atefe Etebari, Mahsa Hajivalili, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 3
Chronic hypoxia is associated with transcriptomic reprogramming and increased genomic instability in cancer cells
Raefa Abou Khouzam, Mohak Sharda, R. Shyama Prasad Rao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 8
Trial watch: anticancer vaccination with dendritic cells
Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, et al.
OncoImmunology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy
Ramia J. Salloom, Iman M. Ahmad, Dania Z. Sahtout, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9195-9195
Open Access | Times Cited: 1
Natural Killer Cells in Anti-Tumour Immunity
Lara V. Graham, Matthew D. Blunt
Elsevier eBooks (2024)
Closed Access
Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer
Laura Svajda, Ivan Ranđelović, Sára Eszter Surguta, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117601-117601
Open Access
Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy
Rishabh Sharma, Manju Kashyap, Hatem Zayed, et al.
Medical & Biological Engineering & Computing (2024)
Closed Access
Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles
Faris Anad Muhammad, Farag M. A. Altalbawy, Viralkumar Mandaliya, et al.
Clinical & Translational Oncology (2024)
Closed Access
Page 1

Scroll to top